27.01.2010 • News

Johnson Matthey Sees Recovery in Key Markets

Johnson Matthey has reported that it had seen the beginnings of recovery in many of its key markets in the last three months of 2009. Sales for the fiscal third quarter excluding precious metals were 9% ahead of a year earlier and underlying pretax profit was up 20% as the company said it continued to benefit from reduced interest costs due to low borrowings and lower interest rates. The company said adjusted pretax profit for the full year is now expected to be slightly ahead of the current market consensus of $391 million.

Company

Johnson Matthey

Orchard Road
SG8 5HE Royston, Herts
UK

Company contact







Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

most read